CD30 ligand oligomers and polypeptides
AssigneeImmunex Corporation
InventorsRaymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
Life of this patent
Estimating the term…
Abstract
There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
Claims8
A purified oligomer comprising CD30 ligand (CD30-L) polypeptides, wherein the CD30-L polypeptides are each selected from the group consisting of:
- a) the murine CD30-L of SEQ ID NO:6;
- b) the murine CD30-L of SEQ ID NO:19;
- c) the human CD30-L of SEQ ID NO:8;
- d) the human CD30-L of SEQ ID NO:23;
- and
- e) a fragment of the CD30-L of (a), (b), (c), or (d), wherein said fragment binds CD30.
A purified CD30-L polypeptide, wherein said polypeptide is a fragment of a protein selected from the group consisting of:
- a) the murine CD30-L protein of SEQ ID NO:6;
- b) the murine CD30-L protein of SEQ ID NO:19;
- c) the human CD30-L protein of SEQ ID NO:8;
- and
- d) the human CD30-L protein of SEQ ID NO:23;
- wherein said fragment binds CD30.
Dependencies are inferred from the claim text.